Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,309 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.
Fernandez-Martinez A, Krop IE, Hillman DW, Polley MY, Parker JS, Huebner L, Hoadley KA, Shepherd J, Tolaney S, Henry NL, Dang C, Harris L, Berry D, Hahn O, Hudis C, Winer E, Partridge A, Perou CM, Carey LA. Fernandez-Martinez A, et al. Among authors: berry d. J Clin Oncol. 2020 Dec 10;38(35):4184-4193. doi: 10.1200/JCO.20.01276. Epub 2020 Oct 23. J Clin Oncol. 2020. PMID: 33095682 Free PMC article. Clinical Trial.
Overestimation of hereditary breast cancer risk.
Iglehart JD, Miron A, Rimer BK, Winer EP, Berry D, Shildkraut MJ. Iglehart JD, et al. Among authors: berry d. Ann Surg. 1998 Sep;228(3):375-84. doi: 10.1097/00000658-199809000-00010. Ann Surg. 1998. PMID: 9742920 Free PMC article.
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.
Costanza ME, Weiss RB, Henderson IC, Norton L, Berry DA, Cirrincione C, Winer E, Wood WC, Frei E 3rd, McIntyre OR, Schilsky RL. Costanza ME, et al. Among authors: berry da. J Clin Oncol. 1999 May;17(5):1397-406. doi: 10.1200/JCO.1999.17.5.1397. J Clin Oncol. 1999. PMID: 10334524 Clinical Trial.
Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support.
Rizzieri DA, Vredenburgh JJ, Jones R, Ross M, Shpall EJ, Hussein A, Broadwater G, Berry D, Petros WP, Gilbert C, Affronti ML, Coniglio D, Rubin P, Elkordy M, Long GD, Chao NJ, Peters WP. Rizzieri DA, et al. Among authors: berry d. J Clin Oncol. 1999 Oct;17(10):3064-74. doi: 10.1200/JCO.1999.17.10.3064. J Clin Oncol. 1999. PMID: 10506601 Clinical Trial.
3,309 results